ArticleNPJ vaccines2023

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.

Samuel Ponce-de-León et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.